Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,153
archived clinical trials in
Gout

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lewes, DE
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lewes, DE
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Boynton Beach, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Brandon, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Clearwater, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Coral Gables, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Coral Springs, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
DeLand, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Doral, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Edgewater, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Edgewater, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Fort Meyers, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Hialeah, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Hollywood, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Homestead, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Homestead, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Jupiter, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
North Bay Village, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
North Bay Village, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Pembroke Pines, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Pinellas Park, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Plant City, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Plant City, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Port Charlotte, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Sanford, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Sanford, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Tallahassee, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Tampa, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Winter Haven, FL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Augusta, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Columbus, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Dunwoody, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Dunwoody, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Fort Valley, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Fort Valley, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Marietta, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Newnan, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Norcross, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Norcross, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Roswell, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Savannah, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Suwanee, GA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Suwanee, GA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Honolulu, HI
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Meridian, ID
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Gurnee, IL
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Gurnee, IL
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Avon, IN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Brownsburg, IN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Brownsburg, IN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Newburgh, IN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Newburgh, IN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Augusta, KA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Augusta, KA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Wichita, KA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Crestview Hills, KY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Crestview Hills, KY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Elizabethtown, KY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Elizabethtown, KY
Click here to add this to my saved trials